GlycoMimetics (GLYC) 10-Q 9 May 24 2024 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 07, 2024
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2024
Entity File Number	001-36177
Entity Registrant Name	GlycoMimetics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	06-1686563
Entity Address, Address Line One	9708 Medical Center Drive
Entity Address, City or Town	Rockville
Entity Address, State or Province	MD
Entity Address, Postal Zip Code	20850
City Area Code	240
Local Phone Number	243-1201
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	GLYC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		64,464,412
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Entity Central Index Key	0001253689
Current Fiscal Year End Date	--12-31
Amendment Flag	false

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 31,281,460	$ 41,792,830
Prepaid expenses and other current assets	1,985,933	1,997,904
Total current assets	33,267,393	43,790,734
Prepaid research and development expenses	192,268	603,737
Operating lease right-of-use asset	598,257	767,828
Other assets	146,995	154,176
Total assets	34,204,913	45,316,475
Current liabilities:
Accounts payable	755,534	868,115
Accrued expenses	3,907,840	5,225,557
Lease liabilities	630,827	741,558
Total current liabilities	5,294,201	6,835,230
Lease liabilities, net of current portion		66,844
Total liabilities	5,294,201	6,902,074
Stockholders' equity:
Preferred stock; $0.001 par value; 5,000,000 shares authorized, no shares issued and outstanding at December 31, 2023 and December 31, 2022
Common stock; $0.001 par value; 100,000,000 shares authorized; 64,393,744 shares issued and outstanding at December 31, 2023; 54,377,798 shares issued and outstanding at December 31, 2022	64,451	64,394
Additional paid-in capital	496,068,140	494,835,219
Accumulated deficit	(467,221,879)	(456,485,212)
Total stockholders' equity	28,910,712	38,414,401
Total liabilities and stockholders' equity	$ 34,204,913	$ 45,316,475

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Balance Sheets
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	64,450,835	64,393,744
Common stock, shares outstanding	64,450,835	64,393,744

Statements of Operations and Co

Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Costs and expenses:
Research and development expense	$ 6,025,461	$ 5,418,706
General and administrative expense	5,089,566	5,522,312
Total costs and expenses	11,115,027	10,941,018
Loss from operations	(11,115,027)	(10,941,018)
Interest income	378,360	581,668
Net loss and comprehensive loss	$ (10,736,667)	$ (10,359,350)
Basic net loss per common share (in dollars per share)	$ (0.17)	$ (0.17)
Diluted net loss per common share (in dollars per share)	$ (0.17)	$ (0.17)
Basic weighted-average number of common shares outstanding (in shares)	64,457,233	60,350,127
Diluted weighted-average number of common shares outstanding (in shares)	64,457,233	60,350,127

Statements of Stockholders' Equ

Statements of Stockholders' Equity - USD ($)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Balance at Dec. 31, 2022	$ 54,378	$ 462,461,251	$ (419,585,792)	$ 42,929,837
Balance, shares at Dec. 31, 2022	54,377,798
Issuance of common stock, net of issuance costs	$ 9,823	28,697,188		28,707,011
Issuance of common stock, net of issuance costs, shares	9,822,930
Exercise of options and vesting of restricted stock units	$ 44	33,724		33,768
Exercise of options and vesting of restricted stock units, shares	44,496
Stock-based compensation		870,180		870,180
Net Income (Loss)			(10,359,350)	(10,359,350)
Balance at Mar. 31, 2023	$ 64,245	492,062,343	(429,945,142)	62,181,446
Balance, shares at Mar. 31, 2023	64,245,224
Balance at Dec. 31, 2023	$ 64,394	494,835,219	(456,485,212)	38,414,401
Balance, shares at Dec. 31, 2023	64,393,744
Issuance of common stock for services	$ 15	35,985		36,000
Issuance of common stock for services, shares	15,256
Exercise of options and vesting of restricted stock units	$ 42	4,856		4,898
Exercise of options and vesting of restricted stock units, shares	41,835
Stock-based compensation		1,192,080		1,192,080
Net Income (Loss)			(10,736,667)	(10,736,667)
Balance at Mar. 31, 2024	$ 64,451	$ 496,068,140	$ (467,221,879)	$ 28,910,712
Balance, shares at Mar. 31, 2024	64,450,835

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Operating activities
Net loss	$ (10,736,667)	$ (10,359,350)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	14,620	43,839
Non-cash lease expense	169,571	219,119
Issuance of common stock for services	36,000
Stock-based compensation	1,192,080	870,180
Changes in assets and liabilities:
Prepaid expenses and other current assets	11,971	(240,103)
Prepaid research and development expenses	411,469
Accounts payable	(112,581)	(490,040)
Accrued expenses	(1,317,717)	(1,383,683)
Lease liabilities	(177,575)	(266,821)
Net cash used in operating activities	(10,508,829)	(11,606,859)	$ (34,900,000)
Investing activities
Purchases of property and equipment	(7,439)	(2,197)
Net cash used in investing activities	(7,439)	(2,197)
Financing activities
Proceeds from issuance of common stock, net of issuance costs		28,707,011
Proceeds from exercise of stock options	4,898	33,768
Net cash provided by financing activities	4,898	28,740,779
Net change in cash and cash equivalents	(10,511,370)	17,131,723
Cash and cash equivalents, beginning of period	41,792,830	47,870,619	47,870,619
Cash and cash equivalents, end of period	$ 31,281,460	$ 65,002,342	$ 41,792,830

Description of the Business

Description of the Business	3 Months Ended
	Mar. 31, 2024
Description of the Business
Description of the Business	GLYCOMIMETICS, INC. Notes to Unaudited Financial Statement s ​ 1. Description of the Business ​ GlycoMimetics, Inc. (the Company), a Delaware corporation headquartered in Rockville, Maryland, was incorporated in 2003. The Company is a late clinical-stage biotechnology company focused on improving the lives of people living with cancer and inflammatory diseases by leveraging the inhibition of carbohydrate interactions that occur on the surface of cells. The Company is developing a pipeline of proprietary glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in important biological processes, to inhibit disease-related functions of carbohydrates such as the roles they play in cancers and inflammation.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2024
Going Concern
Going Concern	2. Going Concern ​ The accompanying unaudited financial statements have been prepared assuming that the Company will continue as a going concern within one year after the date that the financial statements are issued. During 2023, the Company incurred a net loss of $36.9 million and had net cash flows used in operating activities of $34.9 million. At March 31, 2024, the Company had $31.3 million in cash and cash equivalents and had no committed source of additional funding from either debt or equity financings, although the Company may, at its discretion, sell equity securities under the terms of its existing at-the-market sales agreement (see Note 7), subject to certain conditions and limitations. Management believes that given the Company’s current cash position and forecasted negative cash flows from operating activities over the next twelve months, including the continuation of our product development activities, there is substantial doubt about its ability to continue as a going concern after the date that is one year from the date that these unaudited financial statements are issued, without obtaining additional financing or entering into another form of non-equity or debt arrangement. The Company’s ability to fund its operations is dependent upon management’s plans, which include reducing operating expenses and raising additional capital in the near term primarily through a combination of equity and debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements and in the longer term, from revenue related to product sales, to the extent its product candidates receive marketing approval and can be commercialized. There can be no assurances that new financings or other transactions will be available to the Company on commercially acceptable terms, or at all. Also, any collaborations, strategic alliances and marketing, distribution or licensing arrangements may require the Company to give up some or all of its rights to a product or technology, which in some cases may be at less than the full potential value of such rights. If the Company is unable to obtain additional capital, the Company will assess its capital resources and may be required to delay, reduce the scope of or eliminate some or all of its operations, which may have a material adverse effect on its business, financial condition, results of operations and ability to operate as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern. ​

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Significant Accounting Policies
Significant Accounting Policies	3. Significant Accounting Policies ​ There have been no material changes to the significant accounting policies previously disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the United States Securities and Exchange Commission (the SEC) on March 27, 2024 (the Form 10-K). ​ Basis of Accounting ​ The accompanying unaudited financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). ​ Unaudited Financial Statements ​ The accompanying balance sheet as of March 31, 2024, statements of operations and comprehensive loss and stockholders’ equity for the three months ended March 31, 2024 and 2023 and statements of cash flows for the three months ended March 31, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These unaudited financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023 contained in the Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of March 31, 2024, its results of operations and changes in its stockholders’ equity for the three months ended March 31, 2024 and 2023 and its cash flows for the three months ended March 31, 2024 and 2023. The December 31, 2023 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three months ended March 31, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year or for any future period. ​ Use of Estimates ​ The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material. ​ ​ Fair Value Measurements ​ The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of March 31, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $25.2 million and $38.8 million as of March 31, 2024 and December 31, 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three months ended March 31, 2024 and 2023. ​ Concentration of Credit Risk ​ Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents. ​ Revenue Recognition ​ The Company applies Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidates’ rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 10 for additional information regarding the Company’s license agreements. In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success. Licensing of Intellectual Property: Milestone Payments Royalties Manufacturing and Supply: ​ Accruals for Clinical Trial Expenses ​ ​ Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company's clinical trials. Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, estimated project duration and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv) the Company’s judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The Company’s historical clinical accrual estimates have not been materially different from the actual costs. Stock-Based Compensation ​ Stock-based payments are accounted for in accordance with the provisions of ASC 718, Compensation—Stock Compensation ​ The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. ​ A discussion of management’s methodology for developing some of the assumptions used in the valuation model follows: ​ Expected Dividend Yield ​ Expected Volatility ​ Risk-Free Interest Rate ​ Expected Term ​ Net Loss Per Common Share ​ Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock options and restricted stock units (RSUs). ​ The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2024 2023 Stock options and RSUs 13,546,834 11,420,012 ​ Comprehensive Loss Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three months ended March 31, 2024 and 2023, the Company’s net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented. ​ Recently Issued Accounting Standards ​ Accounting Standards Not Yet Adopted There have been no new accounting pronouncements that have significance, or potential significance, to the Company’s unaudited financial statements for the quarter ended March 31, 2024.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	3 Months Ended
	Mar. 31, 2024
Prepaid Expenses and Other Current Assets
Prepaid Expenses and Other Current Assets	4. Prepaid Expenses and Other Current Assets ​ The following is a summary of the Company’s prepaid expenses and other current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ 2024 2023 Prepaid research and development expenses ​ ​ $ 1,016,078 ​ $ 1,420,642 Other prepaid expenses ​ ​ ​ 859,909 ​ ​ 401,442 Other receivables ​ ​ 109,946 ​ 175,820 Prepaid expenses and other current assets ​ ​ $ 1,985,933 ​ $ 1,997,904 ​

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2024
Accrued Expenses
Accrued Expenses	5. Accrued Expenses ​ The following is a summary of the Company’s accrued expenses: ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ ​ 2024 ​ 2023 Accrued research and development expenses ​ $ 1,872,752 ​ $ 1,824,689 Accrued bonuses ​ ​ 666,617 ​ ​ 2,561,913 Accrued consulting and other professional fees ​ 790,989 ​ 439,192 Accrued employee benefits ​ 566,650 ​ 399,763 Other accrued expenses ​ 10,832 ​ — Accrued expenses ​ $ 3,907,840 ​ $ 5,225,557 ​

Operating Leases

Operating Leases	3 Months Ended
	Mar. 31, 2024
Operating Leases
Operating Leases	​ 6. Operating Leases At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the circumstances present. The Company determines a lease exists if the contract conveys the right to control an identified asset for a period of time in exchange for consideration. Control is considered to exist when the lessee has the right to obtain substantially all of the economic benefits from the use of an identified asset as well as direct the right to use of that asset. Leases with a term greater than one year are recognized on the balance sheet as right-of-use assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less on the lease commencement date. If a contract is considered to be a lease, the Company recognizes a lease liability based on the present value of the future lease payments over the expected lease term, with an offsetting entry to recognize a right-of-use asset. The Company has also elected to use the practical expedient and account for each lease component and related non-lease component as one single component. The lease component results in a right-of-use asset being recorded on the balance sheet and amortized as lease expense on a straight-line basis. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a term similar to the term of the lease for which the rate is estimated. Certain adjustments to the right-of-use asset may be required for items such as initial direct costs paid or incentives received. The Company leases office and research space in Rockville, Maryland under an operating lease that is subject to annual rent increases (the Lease). The Company paid a security deposit of $52,320 to be held until the expiration or termination of the Company’s obligations under the Lease. In April 2023, the Company and its landlord entered into an amendment to the Lease (the Lease Amendment). Pursuant to the Lease Amendment, the Company and the landlord agreed that the lease term for a portion of the premises, consisting of approximately 30,000 square feet, would be extended from November 1, 2023 to January 31, 2025. The Company’s lease of the remaining premises, consisting of approximately 12,000 square feet, expired on October 31, 2023. There were no additional operating leases entered into during the quarter ended March 31, 2024. The components of lease expense and related cash flows were as follows: ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2024 2023 Operating lease cost $ 188,310 ​ $ 231,989 Variable lease cost ​ 99,887 ​ ​ 183,274 Total operating lease cost $ 288,197 ​ $ 415,263 ​ ​ ​ ​ ​ ​ Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ Operating cash outflows for operating leases $ 196,314 ​ $ 279,692 ​ Maturities of lease liability due under these lease agreements as of March 31, 2024 were as follows: ​ ​ ​ ​ ​ ​ ​ Operating Lease ​ Obligation April 1, 2024 - December 31, 2024 ​ $ 592,869 2025 ​ ​ 67,401 Thereafter ​ ​ — Total ​ ​ 660,270 Present value adjustment ​ ​ (29,443) Present value of lease payments ​ $ 630,827 ​ Supplemental information related to leases were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, Operating Leases ​ 2024 ​ 2023 Weighted-average remaining lease term (in years) ​ ​ 0.8 ​ ​ 1.1 Weighted-average incremental borrowing rate ​ ​ 10.0% ​ ​ 10.0% ​

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2024
Stockholders' Equity
Stockholders' Equity	7. Stockholders’ Equity ​ At-The-Market Sales Facility ​ In March 2022, the Company filed a shelf registration statement with the SEC, which was declared effective on April 22, 2022. On April 28, 2022, the Company entered into an at-the-market sales agreement (the 2022 Sales Agreement) with Cowen and Company, LLC. Under the 2022 Sales Agreement, the Company may sell up to $100.0 million worth of shares of common stock. During the quarter ended March 31, 2023, the Company issued and sold 9,822,930 shares of common stock under the 2022 Sales Agreement at a weighted average price per share of $3.01, for aggregate net proceeds of $28.7 million, after deducting commissions and offering expenses. There were no shares issued under the 2022 Sales Agreement during the quarter ended March 31, 2024. As of March 31, 2024, approximately $66.0 million remained available to be sold under the terms of the 2022 Sales Agreement. ​ ​

Stock-based Compensation

Stock-based Compensation	3 Months Ended
	Mar. 31, 2024
Stock-based Compensation
Stock-based Compensation	8. Stock-based Compensation 2013 Equity Incentive Plan ​ The Company’s board of directors adopted, and its stockholders approved, its 2013 Equity Incentive Plan effective in January 2014, and the 2013 Equity Incentive Plan was amended and restated by approval of the board of directors in April 2022 and by approval of the stockholders in May 2022 (as so amended and restated, the 2013 Plan). The 2013 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code (the Code), to the Company’s employees and its parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, restricted stock awards, restricted stock unit awards (RSUs), stock appreciation rights, performance stock awards and other forms of stock compensation to its employees, including officers, consultants and directors. The 2013 Plan also provides for the grant of performance cash awards to the Company’s employees, consultants and directors. Unless otherwise stated in a stock option agreement, 25% of the shares subject to an option grant will typically vest upon the first anniversary of the vesting start date and thereafter at the rate of one forty ​ Authorized Shares ​ The maximum number of shares of common stock that may be issued under the 2013 Plan was originally 1,000,000 shares, plus any shares subject to stock options or similar awards granted under the 2003 Plan that expire or terminate without having been exercised in full or are forfeited to or repurchased by the Company. Upon the amendment and restatement of the 2013 Plan in May 2022, the existing share reserve was increased by 2,619,622. Beginning on January 1, 2023 and ending on (and including) January 1, 2029, the maximum number of shares of common stock that may be issued under the 2013 Plan will cumulatively be increased by 4% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lesser number of shares as determined by the board of directors or the compensation committee thereof. ​ Shares issued under the 2013 Plan may be authorized but unissued or reacquired shares of common stock. Shares subject to stock awards granted under the 2013 Plan that expire or terminate without being exercised in full, or that are paid out in cash rather than in shares, will not reduce the number of shares available for issuance under the 2013 Plan. Additionally, shares issued pursuant to stock awards under the 2013 Plan that the Company repurchases or that are forfeited, as well as shares reacquired by the Company as consideration for the exercise or purchase price of a stock award or to satisfy tax withholding obligations related to a stock award, will become available for future grant under the 2013 Plan. ​ A summary of the Company’s stock option activity under the 2013 Plan for the three months ended March 31, 2024 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ WEIGHTED- ​ ​ ​ ​ ​ ​ WEIGHTED- ​ AVERAGE ​ ​ AGGEGATE ​ ​ ​ AVERAGE ​ REMAINING ​ ​ INTRINSIC ​ OUTSTANDING ​ EXERCISE ​ CONTRACTUAL ​ ​ VALUE ​ OPTIONS PRICE TERM (YEARS) ​ (IN THOUSANDS) Outstanding as of December 31, 2023 ​ 8,273,800 ​ $ 5.29 ​ 6.3 ​ ​ ​ Options granted ​ 3,094,500 ​ ​ 3.10 ​ ​ ​ ​ ​ Options exercised ​ (2,800) ​ ​ 1.75 ​ ​ ​ ​ ​ Options forfeited ​ (597,642) ​ ​ 8.21 ​ ​ ​ ​ ​ Outstanding as of March 31, 2024 ​ 10,767,858 ​ ​ 4.50 ​ 7.5 ​ $ 4,028 Vested or expected to vest as of March 31, 2024 ​ 10,615,958 ​ ​ 4.55 ​ 7.6 ​ ​ 3,756 Exercisable as of March 31, 2024 ​ 5,118,477 ​ ​ 6.52 ​ 5.3 ​ ​ 1,758 ​ As of March 31, 2024, there was $10,785,346 of total unrecognized compensation expense related to unvested options under the 2013 Plan that will be recognized over a weighted-average period of approximately 3.5 years. Total intrinsic value of the options exercised during the three months ended March 31, 2024 and 2023 was $3,758 and $23,760, respectively and total cash received for options exercised was $4,898 and $33,768, respectively. The total fair value of stock options which vested in the three months ended March 31, 2024 and 2023 was $1,394,896 and $704,311, respectively. ​ The Company has granted stock options to purchase an aggregate of 151,900 shares to certain employees under the 2013 Plan, the vesting of which is subject to performance vesting conditions relating to the achievement of specified regulatory or commercial milestones. The maximum fair value of $133,820 associated with performance-based options granted has been excluded from the unrecognized compensation expense under the 2013 Plan as the completion of the performance milestones was not deemed to be probable as of March 31, 2024. The Company will reevaluate at the end of each reporting period the probability that the performance conditions will be achieved and will record any adjustments to the compensation cost at that time. ​ An RSU is a stock award that entitles the holder to receive shares of the Company’s common stock as the award vests. The fair value of each RSU is based on the closing price of the Company’s common stock on the date of grant. In January 2021, the Company awarded RSUs under the 2013 Plan to all of its employees. The RSUs granted vest over four years in equal installments on each anniversary of the grant date, provided that the employee remains employed by the Company at the applicable vesting date. Compensation expense is recognized on a straight-line basis. As of March 31, 2024, there was $179,660 of total unrecognized compensation expense associated with outstanding RSU grants that will be recognized over a weighted-average period of approximately 0.8 years. ​ The following is a summary of RSU activity under the 2013 Plan for the three months ended March 31, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Number of Shares ​ Grant Date ​ ​ Underlying RSUs Fair Value Unvested at December 31, 2023 ​ 117,157 ​ $ 3.81 ​ Vested ​ (58,581) ​ 3.81 ​ Unvested at March 31, 2024 ​ 58,576 ​ 3.81 ​ ​ Issuance of Shares to Directors in Lieu of Cash Retainers for Service In March 2023, the Company’s board of directors amended the Company’s Non-Employee Director Compensation Policy to include an election to receive unrestricted shares of common stock in lieu of quarterly board and committee retainer cash payments. The number of shares to be issued to an electing director is determined on the last day of each fiscal quarter by dividing the dollar amount of the compensation to be paid for such quarter that is subject to the election by the closing price of a share of common stock on the last trading day of the fiscal quarter, rounded up to the nearest whole share. Non-employee directors who made such an election will receive 13,127 shares Inducement Plan ​ The Company’s board of directors previously adopted the GlycoMimetics, Inc. Inducement Plan (as amended to date, the Inducement Plan). The Inducement Plan provides for the grant of nonstatutory stock options, restricted stock awards, RSU awards, stock appreciation rights and other forms of stock awards to individuals not previously an employee or director of the Company as an inducement for such individuals to join the Company. Unless otherwise stated in an applicable stock option agreement, one ​ A summary of the Company’s stock option activity under the Inducement Plan for the three months ended March 31, 2024 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ WEIGHTED- ​ ​ ​ ​ ​ WEIGHTED- ​ AVERAGE ​ ​ AGGEGATE ​ ​ ​ AVERAGE ​ REMAINING ​ ​ INTRINSIC ​ OUTSTANDING ​ EXERCISE ​ CONTRACTUAL ​ ​ VALUE ​ OPTIONS PRICE TERM (YEARS) ​ (IN THOUSANDS) Outstanding as of December 31, 2023 ​ 2,590,400 ​ $ 1.97 ​ 8.0 ​ ​ ​ Options granted ​ 130,000 ​ ​ 3.20 ​ ​ ​ ​ ​ Outstanding as of March 31, 2024 ​ 2,720,400 ​ ​ 2.03 ​ 7.8 ​ $ 2,784 Vested or expected to vest as of March 31, 2024 ​ 2,136,200 ​ ​ 2.04 ​ 7.9 ​ ​ 2,184 Exercisable as of March 31, 2024 ​ 1,060,375 ​ ​ 1.98 ​ 7.5 ​ ​ 1,135 ​ As of March 31, 2024, there was $1,621,972 of total unrecognized compensation expense related to unvested options under the Inducement Plan that will be recognized over a weighted-average period of approximately 2.5 years. The total fair value of stock options which vested in the three months ended March 31, 2024 and 2023 was $305,219 and $181,032, respectively. There were no options exercised under the Inducement Plan during the three months ended March 31, 2024 and 2023. ​ The Company has granted stock options to purchase an aggregate of 584,200 shares to certain newly hired employees under the Inducement Plan which options are subject to performance-based vesting conditions. The maximum fair value of $825,353 associated with the performance-based options has been excluded from the unrecognized compensation expense under the Inducement Plan as the completion of the performance milestones was not deemed to be probable as of March 31, 2024. The Company will reevaluate at the end of each reporting period the probability that the performance conditions will be achieved and will record any adjustments to the compensation cost at that time. The weighted-average fair value of the options granted under all equity incentive plans during the three months ended March 31, 2024 and 2023 was $2.44 per share and $2.04 per share, respectively, applying the Black-Scholes-Merton option pricing model utilizing the following weighted-average assumptions: ​ ​ ​ ​ ​ ​ ​ 2024 ​ 2023 Expected term 6.25 years ​ 6.25 years Expected volatility 90.37% ​ 79.56% Risk-free interest rate 3.89% ​ 3.52% Expected dividend yield 0% ​ 0% ​ Stock-based compensation expense was classified on the statements of operations as follows for the three months ended March 31, 2024 and 2023: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2024 ​ 2023 Research and development expense ​ $ 348,242 ​ $ 237,931 General and administrative expense ​ 843,838 ​ 632,249 Total stock-based compensation expense ​ $ 1,192,080 ​ $ 870,180 ​

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2024
Income Taxes
Income Taxes	9. Income Taxes The Company did not record any tax provision or benefit for the three months ended March 31, 2024 and 2023. The Company has provided a valuation allowance for the full amount of its net deferred tax assets since realization of any future benefit from deductible temporary differences, net operating loss carryforwards and research and development credits is not more-likely-than-not to be realized at March 31, 2024 and December 31, 2023.

License and Collaboration Agree

License and Collaboration Agreements	3 Months Ended
	Mar. 31, 2024
License and Collaboration Agreements
License and Collaboration Agreements	10. License and Collaboration Agreements ​ Apollomics ​ In 2020, the Company entered into a collaboration and license agreement (the Agreement) with Apollomics (Hong Kong), Limited (Apollomics) for the development, manufacture and commercialization of products derived from two of the Company’s compounds, GMI-1271 and GMI-1687 (the Products) for therapeutic and prophylactic uses (the Field) in China, Taiwan, Hong Kong and Macau (the Territory). Under the terms of the Agreement, the Company granted Apollomics: ● an exclusive license, with the right to sublicense, to develop, manufacture and have manufactured, distribute, market, promote, sell, have sold, offer for sale, import, label, package and otherwise the Products in the Field in the Territory; and ● a non-exclusive license to conduct preclinical research with respect to Products in the Field outside of the Territory for the purposes of developing such Products for use in the Territory. ​ In 2020, the Company and Apollomics also entered into a clinical supply agreement pursuant to which the Company will manufacture and supply the Products at agreed upon prices. Apollomics has the option to begin manufacture of the Products after appropriate material transfer requirements are met. The Company did not recognize revenue under the clinical supplies agreement during the three months ended March 31, 2024 and 2023. ​ The Company evaluated the Agreement under the provisions of ASC 606 and identified two performance obligations under this revenue arrangement: the (i) delivery of functional licenses and (ii) manufacture and supply of the Products. The initial transaction price consists of a $9.0 million non-refundable up-front payment which was allocated to the delivered functional licenses and recognized in full as revenue in 2020 given that the performance obligation was satisfied upon inception. The Agreement contains various forms of variable consideration, including (i) up to $75.0 million in development milestones based on achievement of certain clinical and regulatory events, (ii) up to $105.0 million of sales-based commercial milestones based on achievement of certain annual net sales targets, (iii) sales-based royalties at specified percentages of net sales ranging from the high single digits to 15%, and (iv) manufacture and supply of clinical and commercial Products. The Company has fully constrained the development milestone consideration using the most likely amount method and will recognize that revenue when it is probable that recognition of revenue related to the milestone will not result in a significant reversal in amounts recognized in future periods, and as such have been excluded from the transaction price. The Company did not recognize any milestone revenue under the Agreement for the three months ended March 31, 2024 and 2023. The Company will recognize revenue related to the sales-based commercial and royalty milestones and royalties at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied), as they were determined to relate predominantly to the licenses granted to Apollomics and, therefore, have been excluded from the transaction price. Lastly, the Company has determined that the consideration for the manufacturing and supply is all variable and is fully constrained. Variable consideration allocated to manufacturing and supply will be recognized at a point in time when the Product is delivered and when the title to the Product is transferred to the customer pursuant to the agreement. The Company reassesses the transaction price in each reporting period and upon the occurrence of a change in circumstances or final resolution of any particular event. ​

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2024
Subsequent Events
Subsequent Events	11. Subsequent Events ​ In April 2024, the Company entered into a purchase commitment with a third-party vendor in the amount of $3,768,000 for 120 kg of raw materials to support manufacturing of its produce candidate uproleselan for commercial supply. Under the agreement, the Company paid a non-refundable advance of $1,130,400 to the vendor. The remainder will be due, if at all, upon completion of the produced quantity. ​ On May 6, 2024, the Company reported topline results from the Company sponsored Phase 3 uproleselan trial, in which uproleselan combined with chemotherapy did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone. Patients treated with uproleselan had a median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the trial. The Company has begun to further evaluate the data with medical, statistical, and regulatory experts and plans to submit the full results for presentation at an upcoming medical meeting. ​

Summary of Significant Accounti

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Significant Accounting Policies
Basis of Accounting	Basis of Accounting ​ The accompanying unaudited financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP).
Unaudited Financial Statements	Unaudited Financial Statements ​ The accompanying balance sheet as of March 31, 2024, statements of operations and comprehensive loss and stockholders’ equity for the three months ended March 31, 2024 and 2023 and statements of cash flows for the three months ended March 31, 2024 and 2023 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete annual financial statements. These unaudited financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2023 contained in the Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and in the opinion of management reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of March 31, 2024, its results of operations and changes in its stockholders’ equity for the three months ended March 31, 2024 and 2023 and its cash flows for the three months ended March 31, 2024 and 2023. The December 31, 2023 balance sheet included herein was derived from audited financial statements, but does not include all disclosures including notes required by GAAP for complete annual financial statements. The financial data and other information disclosed in these notes to the financial statements related to the three months ended March 31, 2024 and 2023 are unaudited. Interim results are not necessarily indicative of results for an entire year or for any future period.
Use of Estimates	Use of Estimates ​ The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Although actual results could differ from those estimates, management does not believe that such differences would be material.
Fair Value Measurements	Fair Value Measurements ​ The Company had no assets or liabilities that were measured using quoted prices for similar assets and liabilities or significant unobservable inputs (Level 2 and Level 3 assets and liabilities, respectively) as of March 31, 2024 and December 31, 2023. The carrying value of cash held in money market funds of $25.2 million and $38.8 million as of March 31, 2024 and December 31, 2023, respectively, is included in cash and cash equivalents and approximates market values based on quoted market prices (Level 1 inputs). The Company did not transfer any assets measured at fair value on a recurring basis between levels during the three months ended March 31, 2024 and 2023.
Concentration of Credit Risk	Concentration of Credit Risk ​ Credit risk represents the risk that the Company would incur a loss if counterparties failed to perform pursuant to the terms of their agreements. Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash balances with financial institutions in federally insured accounts and has cash balances in excess of the insurance limits. Cash equivalents consist of investment in United States government money market funds with major financial institutions. These deposits and funds may be redeemed upon demand and the Company does not anticipate any losses on such balances. The Company has not experienced any losses to date and believes that it is not exposed to any significant credit risk on cash and cash equivalents.
Revenue Recognition	Revenue Recognition ​ The Company applies Accounting Standards Codification, or ASC, Topic 606, Revenue from Contracts with Customers transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods and services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract that falls under the scope of Topic 606, determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. The Company enters into licensing agreements which are within the scope of Topic 606, under which it licenses certain of its drug candidates’ rights to third parties. The terms of these arrangements typically include payment of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; and royalties on net sales of the licensed product, if and when earned. See Note 10 for additional information regarding the Company’s license agreements. In determining the appropriate amount of revenue to be recognized as it fulfills its obligation under each of its agreements, the Company performs the five steps under Topic 606 described above. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement of personnel costs, discount rates and probabilities of technical and regulatory success. Licensing of Intellectual Property: Milestone Payments Royalties Manufacturing and Supply:
Accruals for Clinical Trial Expenses	Accruals for Clinical Trial Expenses ​ ​ Clinical trial costs primarily consist of expenses incurred under agreements with contract research organizations (CROs), investigative sites, laboratory testing expenses, data management and consultants that conduct the Company's clinical trials. Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these clinical trial activities to third parties. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, estimated project duration and other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancellable, and related costs are recorded as research and development expenses as incurred. Except for payments made in advance of services, clinical trial costs are expensed as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, management assessments include: (i) an evaluation by the project manager of the work that has been completed during the period; (ii) measurement of progress prepared internally and/or provided by the third-party service provider; (iii) analyses of data that justify the progress; and (iv) the Company’s judgment. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The Company’s historical clinical accrual estimates have not been materially different from the actual costs.
Stock-Based Compensation	Stock-Based Compensation ​ Stock-based payments are accounted for in accordance with the provisions of ASC 718, Compensation—Stock Compensation ​ The Company has elected to use the Black-Scholes-Merton option pricing model to value any options granted. The Company will reconsider use of the Black-Scholes-Merton model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably estimated using this model. ​ A discussion of management’s methodology for developing some of the assumptions used in the valuation model follows: ​ Expected Dividend Yield ​ Expected Volatility ​ Risk-Free Interest Rate ​ Expected Term
Net Loss Per Common Share	Net Loss Per Common Share ​ Basic net loss per common share is determined by dividing net loss by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net loss per share is computed by dividing net loss by the weighted-average number of common stock equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company’s stock options and restricted stock units (RSUs). ​ The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted-average common shares outstanding, as they would be anti-dilutive: ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2024 2023 Stock options and RSUs 13,546,834 11,420,012
Comprehensive Loss	Comprehensive Loss Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the three months ended March 31, 2024 and 2023, the Company’s net loss equaled comprehensive net loss and, accordingly, no additional disclosure is presented.
Recently Issued Accounting Standards	Recently Issued Accounting Standards ​ Accounting Standards Not Yet Adopted There have been no new accounting pronouncements that have significance, or potential significance, to the Company’s unaudited financial statements for the quarter ended March 31, 2024.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Significant Accounting Policies
Potentially dilutive securities outstanding	​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ ​ 2024 2023 Stock options and RSUs 13,546,834 11,420,012

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Prepaid Expenses and Other Current Assets
Summary of Prepaid Expenses and Other Current Assets	The following is a summary of the Company’s prepaid expenses and other current assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ 2024 2023 Prepaid research and development expenses ​ ​ $ 1,016,078 ​ $ 1,420,642 Other prepaid expenses ​ ​ ​ 859,909 ​ ​ 401,442 Other receivables ​ ​ 109,946 ​ 175,820 Prepaid expenses and other current assets ​ ​ $ 1,985,933 ​ $ 1,997,904 ​

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2024
Accrued Expenses
Summary of Accrued Expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, ​ ​ 2024 ​ 2023 Accrued research and development expenses ​ $ 1,872,752 ​ $ 1,824,689 Accrued bonuses ​ ​ 666,617 ​ ​ 2,561,913 Accrued consulting and other professional fees ​ 790,989 ​ 439,192 Accrued employee benefits ​ 566,650 ​ 399,763 Other accrued expenses ​ 10,832 ​ — Accrued expenses ​ $ 3,907,840 ​ $ 5,225,557 ​

Operating Leases (Tables)

Operating Leases (Tables)	3 Months Ended
	Mar. 31, 2024
Operating Leases
Components of lease expense and related cash flows	​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2024 2023 Operating lease cost $ 188,310 ​ $ 231,989 Variable lease cost ​ 99,887 ​ ​ 183,274 Total operating lease cost $ 288,197 ​ $ 415,263 ​ ​ ​ ​ ​ ​ Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ Operating cash outflows for operating leases $ 196,314 ​ $ 279,692
Maturities of lease liabilities due	​ ​ ​ ​ ​ ​ ​ Operating Lease ​ Obligation April 1, 2024 - December 31, 2024 ​ $ 592,869 2025 ​ ​ 67,401 Thereafter ​ ​ — Total ​ ​ 660,270 Present value adjustment ​ ​ (29,443) Present value of lease payments ​ $ 630,827
Schedule of supplemental information related to leases	​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, ​ December 31, Operating Leases ​ 2024 ​ 2023 Weighted-average remaining lease term (in years) ​ ​ 0.8 ​ ​ 1.1 Weighted-average incremental borrowing rate ​ ​ 10.0% ​ ​ 10.0%

Stock-based Compensation (Table

Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2024
Weighted-Average Fair Value of Options Granted	​ ​ ​ ​ ​ ​ ​ 2024 ​ 2023 Expected term 6.25 years ​ 6.25 years Expected volatility 90.37% ​ 79.56% Risk-free interest rate 3.89% ​ 3.52% Expected dividend yield 0% ​ 0%
Stock-Based Compensation Expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended March 31, ​ 2024 ​ 2023 Research and development expense ​ $ 348,242 ​ $ 237,931 General and administrative expense ​ 843,838 ​ 632,249 Total stock-based compensation expense ​ $ 1,192,080 ​ $ 870,180 ​
2013 Equity Incentive Plan
Company's Stock Option Activity	A summary of the Company’s stock option activity under the 2013 Plan for the three months ended March 31, 2024 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ WEIGHTED- ​ ​ ​ ​ ​ ​ WEIGHTED- ​ AVERAGE ​ ​ AGGEGATE ​ ​ ​ AVERAGE ​ REMAINING ​ ​ INTRINSIC ​ OUTSTANDING ​ EXERCISE ​ CONTRACTUAL ​ ​ VALUE ​ OPTIONS PRICE TERM (YEARS) ​ (IN THOUSANDS) Outstanding as of December 31, 2023 ​ 8,273,800 ​ $ 5.29 ​ 6.3 ​ ​ ​ Options granted ​ 3,094,500 ​ ​ 3.10 ​ ​ ​ ​ ​ Options exercised ​ (2,800) ​ ​ 1.75 ​ ​ ​ ​ ​ Options forfeited ​ (597,642) ​ ​ 8.21 ​ ​ ​ ​ ​ Outstanding as of March 31, 2024 ​ 10,767,858 ​ ​ 4.50 ​ 7.5 ​ $ 4,028 Vested or expected to vest as of March 31, 2024 ​ 10,615,958 ​ ​ 4.55 ​ 7.6 ​ ​ 3,756 Exercisable as of March 31, 2024 ​ 5,118,477 ​ ​ 6.52 ​ 5.3 ​ ​ 1,758
Summary of RSU Activity	​ The following is a summary of RSU activity under the 2013 Plan for the three months ended March 31, 2024: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted-Average ​ ​ Number of Shares ​ Grant Date ​ ​ Underlying RSUs Fair Value Unvested at December 31, 2023 ​ 117,157 ​ $ 3.81 ​ Vested ​ (58,581) ​ 3.81 ​ Unvested at March 31, 2024 ​ 58,576 ​ 3.81 ​
Inducement Plan
Company's Stock Option Activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ WEIGHTED- ​ ​ ​ ​ ​ WEIGHTED- ​ AVERAGE ​ ​ AGGEGATE ​ ​ ​ AVERAGE ​ REMAINING ​ ​ INTRINSIC ​ OUTSTANDING ​ EXERCISE ​ CONTRACTUAL ​ ​ VALUE ​ OPTIONS PRICE TERM (YEARS) ​ (IN THOUSANDS) Outstanding as of December 31, 2023 ​ 2,590,400 ​ $ 1.97 ​ 8.0 ​ ​ ​ Options granted ​ 130,000 ​ ​ 3.20 ​ ​ ​ ​ ​ Outstanding as of March 31, 2024 ​ 2,720,400 ​ ​ 2.03 ​ 7.8 ​ $ 2,784 Vested or expected to vest as of March 31, 2024 ​ 2,136,200 ​ ​ 2.04 ​ 7.9 ​ ​ 2,184 Exercisable as of March 31, 2024 ​ 1,060,375 ​ ​ 1.98 ​ 7.5 ​ ​ 1,135

Description of the Business (De

Description of the Business (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Description of the Business
Accumulated deficit	$ (467,221,879)	$ (456,485,212)

Going Concern (Details)

Going Concern (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Going Concern
Net loss	$ 10,736,667	$ 10,359,350	$ 36,900,000
Net cash flows used in operating activities	10,508,829	$ 11,606,859	34,900,000
Cash and cash equivalents	$ 31,281,460		$ 41,792,830

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Fair Value Measurements (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Fair Value Measurements
Assets transfer measured at fair value	$ 0	$ 0
Level 1
Fair Value Measurements
Carrying value of cash held in money market fund	25,200,000		$ 38,800,000
Level 2
Fair Value Measurements
Assets measured at fair value levels 2 or 3	0		0
Liabilities measured at fair value levels 2 or 3	0		0
Level 3
Fair Value Measurements
Assets measured at fair value levels 2 or 3	0		0
Liabilities measured at fair value levels 2 or 3	$ 0		$ 0

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Potentially Dilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stock options and restricted stock units
Anti-dilutive securities	13,546,834	11,420,012

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Stock-Based Compensation (Details)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Defined Contribution Plan Disclosure
Expected term	6 years 3 months	6 years 3 months
Maximum
Defined Contribution Plan Disclosure
Expiration period	10 years

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Prepaid Expenses and Other Current Assets
Prepaid research and development expenses	$ 1,016,078	$ 1,420,642
Other prepaid expenses	859,909	401,442
Other receivables	109,946	175,820
Prepaid expenses and other current assets	$ 1,985,933	$ 1,997,904

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Accrued Expenses
Accrued research and development expenses	$ 1,872,752	$ 1,824,689
Accrued bonuses	666,617	2,561,913
Accrued consulting and other professional fees	790,989	439,192
Accrued employee benefits	566,650	399,763
Other accrued expenses	10,832
Accrued expenses	$ 3,907,840	$ 5,225,557

Operating Leases (Details)

Operating Leases (Details)	3 Months Ended
	Mar. 31, 2024 lease	Apr. 30, 2023 ft²	May 31, 2016 USD ($)
Operating leases
Lease, Practical Expedient, Lessor Single Lease Component [true false]	true
Security Deposit | $			$ 52,320
Number of additional operating leases entered during the period | lease	0
First portion of Rockville, Maryland lease
Operating leases
Square feet leased		30,000
Lessee, Operating Lease, Existence of Option to Extend [true false]	true
Second portion of Rockville, Maryland lease
Operating leases
Square feet leased		12,000

Operating Leases - Components o

Operating Leases - Components of lease expense (Details)	3 Months Ended
	Mar. 31, 2024 USD ($)
Components of lease expense
Operating lease cost	$ 188,310
Variable lease cost	99,887
Total operating lease cost	288,197
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash outflows for operating leases	$ 196,314

Operating Leases - Maturities o

Operating Leases - Maturities of lease liability (Details)	Mar. 31, 2024 USD ($)
Maturities of lease liability due
April 1, 2024 - December 31, 2024	$ 592,869
2025	67,401
Thereafter
Total	660,270
Present value adjustment	(29,443)
Present value of lease payments	$ 630,827
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]	Operating Lease, Liability, Current, Operating Lease, Liability, Noncurrent

Operating Leases - Supplemental

Operating Leases - Supplemental Information (Details)	Mar. 31, 2024	Dec. 31, 2023
Operating Leases
Weighted-average remaining lease term (in years)	9 months 18 days	1 year 1 month 6 days
Weighted-average incremental borrowing rate	10%	10%

Stockholders' Equity (Details)

Stockholders' Equity (Details) - 2022 Sales Agreement - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Mar. 31, 2022
Equity offerings
Issuance of common stock, net of issuance costs, shares	0	9,822,930
Price per share		$ 3.01
Aggregate net proceeds from stock sale		$ 28.7
Common stock available for sale under agreement	$ 66
Maximum
Equity offerings
Common stock available for sale under agreement			$ 100

Stock-based Compensation - Ince

Stock-based Compensation - Incentive Plans (Details) - USD ($)	1 Months Ended			3 Months Ended
	May 31, 2022	Jan. 31, 2022	Jan. 31, 2014	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Incentive plans
Fair value of shares vested				$ 305,219	$ 181,032
2013 Equity Incentive Plan
Incentive plans
Percent of shares subject to option grant that will vest			25%
Period from date of termination that any vested options shall expire			90 days
Expiration period			10 years
Unrecognized compensation expense related to unvested options				$ 10,785,346
Period for unrecognized compensation expense related to unvested options yet has not been recognized				3 years 6 months
Intrinsic value of options exercised				$ 3,758	23,760
Cash proceeds from exercise of stock options				$ 4,898	33,768
Shares issued from exercise of stock options				2,800
Fair value of shares vested				$ 1,394,896	$ 704,311
Authorized shares
Common stock authorized			1,000,000	14,257,627
Shares available for future grants				2,597,377
Maximum number of shares that may be issued pursuant to exercise of incentive stock options			20,000,000
Increase in number of shares of common stock	2,619,622
Maximum percentage of shares of common stock issued and outstanding on the immediately preceding fiscal year, or such lesser number of shares as determined by the board of directors or the compensation committee						4%
2013 Equity Incentive Plan | Stock options vesting based on performance
Incentive plans
Maximum fair value of option excluded from the unrecognized compensation expense				$ 825,353
2013 Equity Incentive Plan | Stock options vesting based on performance | Employees
Incentive plans
Maximum fair value of option excluded from the unrecognized compensation expense		$ 133,820
2013 Equity Incentive Plan | RSU
Incentive plans
Unrecognized compensation expense related to RSU grants				$ 179,660
2013 Equity Incentive Plan | RSU | Employees
Incentive plans
Period for unrecognized compensation expense related to unvested options yet has not been recognized				9 months 18 days
2013 Equity Incentive Plan | Each month after the first anniversary
Incentive plans
Percent of shares subject to option grant that will vest			2.08%

Stock-based Compensation - Comp

Stock-based Compensation - Company's Stock Option Activity (Details) - 2013 Equity Incentive Plan - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2022	Mar. 31, 2024	Dec. 31, 2023
OUTSTANDING OPTIONS
Outstanding at beginning of period		8,273,800
Options granted		3,094,500
Options exercised		(2,800)
Options forfeited		(597,642)
Outstanding at end of period		10,767,858	8,273,800
WEIGHTED-AVERAGE EXERCISE PRICE
Outstanding at beginning of period		$ 5.29
Options granted		3.10
Options exercised		1.75
Options forfeited		8.21
Outstanding at end of period		$ 4.50	$ 5.29
VESTED AND EXPECTED TO VEST
Outstanding options		10,615,958
Weighted-Average Exercise Price		$ 4.55
Weighted-Average Remaining Contractual Term		7 years 7 months 6 days
Aggregate Intrinsic Value (in thousands)		$ 3,756
ADDITIONAL DISCLOSURES
Outstanding options exercisable at end of period		5,118,477
Weighted-average exercise price exercisable at end of period		$ 6.52
Weighted-average contractual term outstanding		7 years 6 months	6 years 3 months 18 days
Weighted-average contractual term (years) exercisable		5 years 3 months 18 days
Aggregate intrinsic value (in thousands) outstanding at end of period		$ 4,028
Aggregate intrinsic value (in thousands) exercisable at end of period		$ 1,758
Employees | Stock options vesting based on performance
OUTSTANDING OPTIONS
Options granted	151,900
Newly hired employees | Stock options vesting based on performance
OUTSTANDING OPTIONS
Options granted		584,200

Stock-based Compensation - Summ

Stock-based Compensation - Summary of RSU Activity (Details) - 2013 Equity Incentive Plan	3 Months Ended
	Mar. 31, 2024 $ / shares shares
Restricted Stock Units information
Period for unrecognized compensation expense related to unvested options yet has not been recognized	3 years 6 months
RSU
NUMBER OF SHARES
Unvested at beginning of period | shares	117,157
Vested | shares	(58,581)
Unvested at end of period | shares	58,576
WEIGHTED-AVERAGE GRANT DATE FAIR VALUE
Unvested at beginning of period | $ / shares	$ 3.81
Vested | $ / shares	3.81
Unvested at end of period | $ / shares	$ 3.81
RSU | Employees
Restricted Stock Units information
Vesting period	4 years
Period for unrecognized compensation expense related to unvested options yet has not been recognized	9 months 18 days

Stock-based Compensation - Issu

Stock-based Compensation - Issuance of Shares to Directors in Lieu of Cash Retainers for Service (Details) - Non-employee - Other Awards - Director	3 Months Ended
	Mar. 31, 2024 shares
Share-based Compensation Arrangement by Share-based Payment Award
Common stock shares issued	13,127
Share-Based Payment Arrangement, Grantee Status [Extensible Enumeration]	Non-employee

Stock-based Compensation - Indu

Stock-based Compensation - Inducement Plan (Details)	1 Months Ended		3 Months Ended
	Jan. 31, 2022 shares	Jan. 31, 2020 installment	Mar. 31, 2024 USD ($) shares	Mar. 31, 2023 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award
Fair value of shares vested | $			$ 305,219	$ 181,032
Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award
Period from date of termination that any vested options shall expire		90 days
Expiration period		10 years
Unrecognized compensation expense related to unvested options | $			$ 1,621,972
Period for unrecognized compensation expense related to unvested options yet has not been recognized			2 years 6 months
Options granted			130,000
Options exercised			0	0
Inducement Plan | Upon first anniversary of start date
Share-based Compensation Arrangement by Share-based Payment Award
Vesting percentage		25%
Inducement Plan | Each month after the first anniversary
Share-based Compensation Arrangement by Share-based Payment Award
Number of monthly installments | installment		36
Common Stock | Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award
Increase in number of shares of common stock	3,000,000
Shares available for future grants			269,508

Stock-based Compensation - In_2

Stock-based Compensation - Inducement Plan - Stock Option Activity (Details) - Inducement Plan - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
OUTSTANDING OPTIONS
Outstanding at beginning of period	2,590,400
Options granted	130,000
Outstanding at end of period	2,720,400	2,590,400
WEIGHTED-AVERAGE EXERCISE PRICE
Outstanding at beginning of period	$ 1.97
Options granted	3.20
Outstanding at end of period	$ 2.03	$ 1.97
VESTED AND EXPECTED TO VEST
Outstanding options	2,136,200
Weighted-Average Exercise Price	$ 2.04
Weighted-Average Remaining Contractual Term	7 years 10 months 24 days
Aggregate Intrinsic Value (in thousands)	$ 2,184
ADDITIONAL DISCLOSURES
Outstanding options exercisable at end of period	1,060,375
Weighted-average exercise price exercisable at end of period	$ 1.98
Weighted-average contractual term outstanding	7 years 9 months 18 days	8 years
Weighted-average contractual term (years) exercisable	7 years 6 months
Aggregate intrinsic value (in thousands) outstanding at end of period	$ 2,784
Aggregate intrinsic value (in thousands) exercisable at end of period	$ 1,135

Stock-based Compensation - Weig

Stock-based Compensation - Weighted-Average assumptions (Details) - $ / shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Weighted-average assumptions
Expected term	6 years 3 months	6 years 3 months
Expected volatility	90.37%	79.56%
Risk-free interest rate	3.89%	3.52%
Expected dividend yield	0%	0%
2013 Equity Incentive and Inducement Plan
Share-based Compensation Arrangement by Share-based Payment Award
Weighted-average fair value of the options granted	$ 2.44	$ 2.04

Stock-based Compensation - Stoc

Stock-based Compensation - Stock-Based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stock-based compensation expense
Total stock-based compensation expense	$ 1,192,080	$ 870,180
Research and development expense
Stock-based compensation expense
Total stock-based compensation expense	348,242	237,931
General and administrative expense
Stock-based compensation expense
Total stock-based compensation expense	$ 843,838	$ 632,249

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Taxes
Income tax (benefit) provision	$ 0	$ 0

License and Collaboration Agr_2

License and Collaboration Agreements (Details) - Apollomics, Inc. $ in Millions	3 Months Ended
	Mar. 31, 2020 USD ($)
Research and License Agreements
Up-front payment received	$ 9
Milestones based on achievement of certain clinical and regulatory events	75
Milestone payment upon achievement of specified net sales thresholds for all licensed products	$ 105
Maximum
Research and License Agreements
Tiered percentage of annual net sales	15%

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event		1 Months Ended
	May 06, 2024	Apr. 30, 2024 USD ($) kg
Treated patients within clinical trial | Median
Subsequent Event
Survival period for participants in clinical trial	13 months
Patients within placebo group of clinical trial | Median
Subsequent Event
Survival period for participants in clinical trial	12 months 9 days
Raw materials
Subsequent Event
Minimum amount to purchase raw materials		$ 3,768,000
Minimum kilograms required to purchase | kg		120
Non-refundable advance to vendor		$ 1,130,400

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (10,736,667)	$ (10,359,350)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false